UNSPSC 51351911: Ulipristal

This classification denotes an anti-progestin, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6J5J15Q2X8. European Medicines Agency schedules Ulipristal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30471. Ulipristal generally arises in the molecular formula C28H35NO3. The term ULIPRISTAL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21, no. 3, 2007, list 58.) As of Q4 2014, ULIPRISTAL remains the US FDA Preferred Term for this commodity.

Ulipristal bears US NLM identifiers UMLS ID C0300205 and NCI Concept Code C91056. SMILES: CC(=O)C1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O.

UNSPSC 51351911 Ulipristal, a Commodity code, encompasses emergency contraceptive pharmaceuticals supplied through state and local cooperative purchasing agreements to participating government facilities, including prisons, health departments, and emergency response centers. The recent activity under this code reflects demand for generic and brand-name pharmaceutical products distributed via authorized wholesaler networks under multi-year cooperative contracts. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, dominates recent solicitation activity, issuing RFPs to establish multiple pharmaceutical supply agreements serving state and local members across multiple jurisdictions including Oregon. Issuing bodies under this code include state departments of administration and health, counties, and municipalities accessing pharmaceuticals through cooperative purchasing vehicles rather than individual procurement actions; repeat buyers operate through established wholesaler networks (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co.) requiring vendors to maintain inventory and chargeback systems.

Geographic activity centers on the Upper Midwest and Pacific Northwest, with MMCAP's multistate membership anchoring recent procurement. MMCAP issued a Request for Proposal (S1070000015802) on January 20, 2026, closing March 26, 2026, to establish contracts for generic multi-source pharmaceuticals and OTC products effective July 1, 2026, with a two-year initial term and optional extensions through June 30, 2028. Vendors must certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain relationships with at least two of three authorized wholesalers, provide detailed product information including National Drug Codes and packaging configurations, and submit pricing in flat-price, net-price, or WAC-minus formats. Evaluation prioritizes price competitiveness (75 percent), followed by fixed pricing, administrative compliance, EDI capability, and acceptance of a 3 percent administrative fee. No specific set-aside designations were identified in the available solicitation materials; all products must meet FDA requirements and possess minimum six-month shelf life from manufacture.